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Introduction: Chronic rhinosinusitis (CRS) is an inflammatory condition that affects the nose and 
paranasal sinuses, characterised by nasal purulent discharge, nasal blockage and hyposmia, in combination 
with facial pain/pressure for at least 12 weeks. CRS can be classified as chronic rhinosinusitis with nasal 
polyps (CRSwNP) and chronic rhinosinusitis without nasal polyps (CRSsNP). Asthma is a complex chronic 
inflammatory disorder that presents a lot of different phenotypes and endotypes. Eosinophilic asthma is a 
specific phenotype characterised by thickening of the basement membrane and good response to 
corticosteroid. IL-5 is the most important interleukin responsible for eosinophilic airway inflammation.  
Material and methods: Patients with severe eosinophilic asthma were enrolled into a study group for 
the administration of anti-IL-5 (Mepolizumab) for severe eosinophilic asthma in a single specialised 
pulmonary tertiary institution. All patients were evaluated of their nasal status by a rhinologist for nasal 
symptoms regarding EPOS criteria, comorbidities (smoking, family history of CRS, allergies, VAS scale of 
asthma state, gastroesophageal reflux disease) and completed the validated SNOT-22 questionnaire on the 
same day before the administration of the anti-IL-5. Two separate biopsies were taken from the uncinate 
process or middle concha or nasal polyps, one for histopathology, the other for immunology. All patients had 
computer tomography scan of the paranasal sinuses and blood specimens taken for eosinophilia in the 
peripheral blood. The histopathological disease was characterised by counting of the eosinophils in high 
power field (HPF). Positive results were regarded when the count was higher than 10 per HFP. The 
immunologic study was performed by the RNA-sequencing. Hypereosinophilia was defined by a percentage 
count higher than 4% with a corresponding count higher than 500 per cubic mm.  
Results: The study is still in progress, currently including 9 patients, 6 with CRS and 3 without. 
Preliminary results show no statistically significant differences between the groups. Unfortunately, the data 
about the postinterventional results of our patients is not available yet.  
Conclusion: Literature shows improvement in radiologic findings and quality of life markers with 
Mepolizumab use.  
Key words: chronic rhinosinusitis, asthma, mepolizumab 
 
